FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 103 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults June 15, 2023 Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... August 5, 2019 Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... April 17, 2024 Load more HOT NEWS ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después... Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes Ensuring a Smooth Leadership Transition at NCI
